Mike Havrilla
Long-term horizon

Merrimack Poised For Post-Offering Bounce Ahead Of Phase III Results

Merrimack Pharma (NASDAQ:MACK) is a cancer biotech with a diverse early-late stage clinical development pipeline that is summarized below.

CLINICAL TRIAL CATALYSTS (status updated in 7/12 SEC 424B5 prospectus filing related to recent offering):

1.) MM-398 (novel encapsulated liposomal formulation of approved anti-cancer drug irinotecan) is currently being evaluated in a Phase III (NAPOLI-1) clinical trial with expected completion of enrollment during Q3 2013 and top-line results expected during Q4 2013 to Q1 2014.

MM-398 is being evaluated for the treatment of metastatic pancreatic cancer that has progressed on gemcitabine treatment (i.e. a second-line treatment indication). ClinicalTrials.gov ID NCT01494506 is the identifier for the study and MM-398 has US and EU Orphan Drug status and the drug is...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details